Prof. Jamal Mahajna : Plant-Based Cancer Drugs
Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells.
Koren Carmi, Y., Agbarya, A., Khamaisi, H., Farah, R., Shechtman, Y., Korobochka, R., Gopas, J., Mahajna, J.
2024
,
Translational Oncol. 10.1016/j.tranon.2024.101939
Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer
Wang, J., Beghelli, D., Amici, A., Sut, S., Dall’Acqua, S., Lupidi, G., Dal Ben, D., Bistoni, O., Tomassoni, D., Belletti, B., Musa, S., Mahajna, J., Pucciarelli, S., & Marchini, C.
2024
,
Biomolecules, 14(11), 1454
Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells
Yifat Koren Carmi, Abed Agbarya, Hazem Khamaisi, Raymond Farah, Yelena Shechtman, Roman Korobochka, Jacob Gopas, Jamal Mahajna
2024
Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to OC cells and JAK and c-MET kinase inhibitors restore platinum sensitivity to ovarian cancer cells
Yifat Koren Carmi, Hazem Khamaisi, Jacob Gopas and Jamal Mahajna
2023
,
Int. J. Mol. Sci. 2023, 24(9), 7730;
Plant-derived epi-nutraceuticals as Potential Broad-Spectrum Anti-Viral Agents
Gabbianelli, R.; Shahar, E.; De Simone, G.; Rucci, C.; Bordoni, L.; Feliziani, G.; Zhao, F.; Ferrati, M.; Maggi, F.; Spinozzi, E.; Mahajna, J.
2023
,
Nutrients 2023, 15(22), 4719;
Compounds originating from the edible mushroom Auricularia auricula-judae inhibit tropomyosin receptor kinase B activity
Orr Shahar, Idan Pereman, Hazem Khamisie, Nirit Ezov, Ofer Danay, Ali Khattib, Ron schweitzer, Soliman Khatib and Jamal Mahajna
2023
,
Heliyon, e13756
TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer
Jonathan Zorea, Yair Motro, Roei D. Mazor, Yifat Koren Carmi, Ziv Shulman, Jamal Mahajna, Jacob Moran-Gilad and Moshe Elkabets
2023
,
J Exp Clin Cancer Res, 42(1):107.
doi: 10.1186/s13046-023-02680-7.
doi: 10.1186/s13046-023-02680-7.
2-hydroxyestradiol overcomes mesenchymal stem cells-mediated platinum chemoresistance in ovarian cancer cells in an ERK-independent fashion
Khamaisi, H.; Mahmoud, H.; Mahajna, J.
2022
,
Molecules, 27(3), 804;
Natural products counteracting cardiotoxicity during cancer chemotherapy: The special case of doxorubicin, a comprehensive review
Izabela Koss-Mikołajczyk, Vanja Todorovic, Sladjana Sobajic, Jamal Mahajna, Marko Gerić, Josep A Tur, Agnieszka Bartoszek
2021
,
International Journal of Molecular Sciences, 22(18), 10037
Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
Regev, O., Kidan, N., Nicola, M., Hazem Khamisie, H., Ruthardt M and Mahajna, J.
2021
,
Archive in Medical sciences. 17(1): 266–274.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants
Mian, AA, Haberbosch, I., Khamaisie, H., Agbarya, A., Pietsch, L., Eshel, E., Dally, N., Claudia Chiriches, C., Ottmann, O., Hantschel, O., Biondi, R., Ruthardt, M., and Mahajna, J.
2021
,
BCR/ABL1T315I and BCR/ABL1T315I-E255K. Annals of Hematology 100, pages2023–2029
Flavonoids targeting cancer stem cells for augmenting cancer therapeutics.
Meerson A, Khatib S, Mahajna J.
2021
,
Int. J. Mol. Sci. 22(23), 13044
The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics.
Prša P, Karademir B, Biçim G, Mahmoud H, Dahan I, Yalçın AS, Mahajna J, Milisav I.
2019
,
Biochem Pharmacol. 2020 Mar;173:113551. doi: 10.1016/j.bcp.2019.06.007. Epub 2019 Jun 8. Review
Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential
Kidan N, Khamaisie H, Ruimi N, Roitman S, Eshel E, Dally N, Ruthardt M, Mahajna J.
2017
,
In J Cancer ,2017, Ed. , , Pages 3952-3968
Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach
Ben-Arye E, Lavie O, Samuels N, Khamaisie H, Schiff E, Gressel Raz O, Mahajna J.
2017
,
Medical Oncology 2017 Volume 34 Issue 4 Pages 54
The anti-proliferative and anti-androgenic activity of different pomegranate accessions.
Orgil O, Spector L, Holland D, Mahajna J, Amir R.
2016
,
Journal of Functional Foods 2016 Volume 26 Pages 517?528
Exploring an herbal "wonder cure" for cancer: a multidisciplinary approach.
Ben-Arye E, Mahajna J, Aly R, Ali-Shtayeh MS, Bentur Y, Lev E, Deng G, Samuels N.
2016
,
J Cancer Res Clin Oncol. 2016 Volume 142 Issue 7 Pages 1499-508
Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study
Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.
2016
,
BMC Cancer 2016 Volume 16 Issue 1 Pages 140
Sustained Proliferation in Cancer: Mechanisms and Novel Therapeutic Targets
Feitelson, M., Arzumanyan, A., Kulathinal, R., Blain, S., Holcombe, R., Mahajna, J., et al.,
2015
,
Semin Cancer Biol. 2015 Volume 35 Issue supplement Pages S25?S54
Natural products as potential cancer therapy enhancers: A preclinical update.
Agbarya, A., Ruimi, N., Epelbaum, R., Ben-Arye, E. and Mahajna, J.
2014
,
SAGE Open Medicine 2014 Volume 2 Pages 1-12
The antioxidative and anti-proliferative potential of non-edible organs of the pomegranate fruit and tree.
Orgil, O, Schwartz, E, Matityahu, I, Mahajna, J. and Amir,R.
2014
,
LWT - Food Science and Technology 2014 Volume 58 Issue 2 Pages 571-577
Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines
Y. Najajreh; H. Khamaisie; N. Ruimi; S. Khatib; J. Katzhendler; M. Ruthardt; J. Mahajna
2013
,
Molecular Biology Reports 2013 Volume 40 Issue 3 Pages 2205-2213
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
A. A. Mian; A. Metodieva; S. Badura; M. Khateb; N. Ruimi; Y. Najajreh; O. G. Ottmann; J. Mahajna; M. Ruthardt
2012
,
BMC Cancer 2012 Volume 12
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
M. Khateb; N. Ruimi; H. Khamisie; Y. Najajreh; A. Mian; A. Metodieva; M. Ruthardt; J. Mahajna
2012
,
BMC Cancer 2012 Volume 12
p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia
A. A. Mian; A. Metodieva; Y. Najajreh; O. G. Ottmann; J. Mahajna; M. Ruthardt
2012
,
Haematologica 2012 Volume 97 Issue 2 Pages 251-257